Search
Pregnancy and birth cohorts have been utilised extensively to investigate the developmental origins of health and disease, particularly in relation to...
This study investigated whether a prior bout of moderate-intensity exercise attenuates the glycemia-increasing effect of a maximal 30-sec sprint.
Besides the challenges associated with their teenage years, adolescents with Type 1 Diabetes (T1D) encounter additional challenges of having a chronic condition.
Co-head, Diabetes and Obesity Research
Research Assistant
Liz Tim Davis Jones MBBS FRACP PhD MBBS DCH FRACP MD Co-director of Children’s Diabetes Centre Co-head, Diabetes and Obesity Research Co-director of
Aveni Liz Haynes Davis BA (Hons), MBBChir, MA (Cantab), PhD MBBS FRACP PhD Principal Research Fellow Co-director of Children’s Diabetes Centre
Parents of young children with type 1 diabetes (T1D) are at risk of experiencing elevated stress due to their responsibilities as caregivers. Despite this, there are limited interventions designed to enhance resilience in this population of parents. This pilot randomised controlled trial aimed to examine the acceptability, appropriateness, and feasibility of the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention in parents of young children with T1D.
Studies of traditional Indigenous compared to 'Western' gut microbiomes are underrepresented, and lacking in young children, limiting knowledge of early-life microbiomes in different cultural contexts. Here we analyze the gut metagenomes of 50 Indigenous Australian infants (median age <one year) living remotely with variable access to Western foods, compared to age- and sex-matched non-Indigenous infants living in urban Australia.
Advanced hybrid closed-loop (AHCL) therapy improves glycemia. However, it is not known if there is an improvement in overall outcomes with AHCL for youth with type 1 diabetes (T1D) at high risk of diabetes-related complications. The study aimed to capture the experiences of youth with suboptimal glycemic control when commencing AHCL therapy in a clinical trial setting.